• Events
  • Scientific Seminar on Partnering with KOLs and Sites in the…

Scientific Seminar on Partnering with KOLs and Sites in the US and Europe

Discover Strategies for Partnering with KOLs and Sites in the US and Europe to Enhance Performance in Clinical Trials with Ergomed at Scientific Seminar in Taiwan, in collaboration with TRPMA.

Efficient partnering with sites and KOLs is a key success factor for clinical trial conduct and bringing new therapies to patients. TRPMA has partnered with Ergomed to host a seminar on “Strategies for Partnering with KOLs and Sites in the US and Europe to Enhance Performance in Clinical Trials” on March 19th, 2024. The event is designed to equip innovative pharmaceutical and biotech companies with essential strategies for successful collaboration with key opinion leaders (KOLs) and clinical sites in the US and Europe.

The seminar will cover a wide range of topics, from the initial selection and engagement of top investigators and sites to sustaining effective partnerships and addressing site-specific needs and challenges. Special attention will be given to the importance of customizing approaches to accommodate the unique aspects of each site, country, therapeutic area and study protocol characteristics.

See full agenda

 

Date and Time: March 19, 2023 (Tuesday) 14:00-17:00

Venue: TRPMA Conference Hall
(1F, No. 465-1, Section 6, Zhongxiao East Road, Nangang District, Taipei City)

Contact:Vian Yeh (02)2783-1262 trpma@trpma.org.tw

 

 

Expert Speaker


Juliet Moritz
Senior Vice President of Strategic Solutions & Patient Centricity, Ergomed

Juliet has over 30 years of global biotech research industry experience across multiple therapeutic areas, spanning Phases I-IV. Juliet brings extensive experience in rare diseases, advanced therapies, and complex trials. Her work ensures clinician engagement and patient voices are integral to the drug development process, enhancing outcomes. She has a doctorate in Bioethics, a Master’s in Public Health, holds a Professional Certification in Genetics/Genomics and is a Level I certified Professional Patient Advocate in the Life Sciences (PPALS).

 

Seminar Panelists


Dave Selkirk
President, Ergomed Clinical Research

Dave is a seasoned industry executive and President at Ergomed CRO. Dave graduated from the University of Western Ontario with a BSc in Biology and brings over 3 decades of experience in the Biotech and Pharma Research industry. His experience spans all therapeutic areas and phases of clinical trials, as well as pre-clinical research, central & esoteric labs, post-marketing/market access, along with clinical trial technology. He has a broad international perspective from N. America, Europe, APAC, and LATAM, including a broad list of Sites of excellence and KOLs he has worked with in his career.

 


Yun Yen
President, TiBIA

Dr. Yen received a M.D. from Taipei Medical College in 1982 and a Ph.D. in Pathology and Cell Biology from Thomas Jefferson University in 1988. Dr. Yen serves as an Adjunct Professor at Case Western Reserve University and California Institute of Technology, as well as an Emeritus President at Taipei Medical University in Taiwan. Dr. Yen’s prior experience includes service as the Allen and Lee Chao Endowed Chair in Developmental Cancer Therapeutics at the City of Hope Comprehensive Cancer Center from 2008 until 2014, Chair of the City of Hope’s Molecular Pharmacology Department, Interim Chair at the City of Hope Medical Oncology, and Associate Director for Translational Research at the City of Hope Comprehensive Cancer Center from 2005 until 2014. Dr. Yen holds memberships or fellowships in numerous professional organizations, including National Academy of Inventors, Russian Academy of Engineering, and American Association for the Advancement of Science, and has published more than 343 peer-reviewed journal articles.

 


George Yeh
Standing Director, TRPMA
President, TLC BioSciences

George Yeh is the Standing Director at TRPMA and President of TLC BioSciences. George is responsible for strategic planning of the TLC’s drug programs, business operations, corporate development, product licensing, and management of corporate funding. George was previously Vice President of AsiaWired Group, Inc., a venture advisory company, and Chief Financial Officer of Hermes Biosciences, now a part of Merrimack Pharmaceuticals. George received his Master of Architecture and MBA from the University of Michigan – Ann Arbor and his BA in Architecture from the University of California, Berkeley.

 

 

Contact us for support with Partnering with KOLs and Sites.

 

This site uses cookies to personalize and customize your experience. By clicking “I Accept", you consent to cookies in accordance with our privacy policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.


  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services
Secured By miniOrange